AbCellera Biologics (ABCL) Return on Capital Employed (2021 - 2026)
AbCellera Biologics (ABCL) posted Return on Capital Employed of 16.5% for Q1 2026, up 1.8% on a QoQ basis from 16.8% in Q4 2025, and up 876.0% year-over-year from 1.69% in Q1 2025.
AbCellera Biologics (ABCL) Return on Capital Employed (2021 - 2026) Analysis & Trends
AbCellera Biologics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 16.5% for Q1 2026.
- Quarterly Return on Capital Employed rose 876.0% year-over-year to 16.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.5% (up 876.0% YoY) and the FY2025 annual result came in at 16.77%, up 658.0% from the prior year.
- Return on Capital Employed was 16.5% for Q1 2026 at AbCellera Biologics, up from 16.8% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 22.89% in Q3 2022 and bottomed at 25.26% in Q1 2025.
- A 5-year average of 8.79% and a median of 16.58% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed sank 3766 bps — and 2026, when it surged 876 bps.
- AbCellera Biologics' Return on Capital Employed stood at 15.16% in 2022, then tumbled by 213 bps to 17.17% in 2023, then slumped by 41 bps to 24.21% in 2024, then jumped by 31 bps to 16.8% in 2025, then rose by 2 bps to 16.5% in 2026.
- Business Quant data shows ABCL's Return on Capital Employed at 16.5% in Q1 2026, 16.8% in Q4 2025, and 19.94% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | AbCellera Biologics | 1.72 Bn | 1.72 Bn | - | -16.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.50% |
| Dec 31, 2025 | -16.80% |
| Sep 30, 2025 | -19.94% |
| Jun 30, 2025 | -21.34% |
| Mar 31, 2025 | -25.26% |
| Dec 31, 2024 | -24.21% |
| Sep 30, 2024 | -23.28% |
| Jun 30, 2024 | -19.69% |
| Mar 31, 2024 | -16.58% |
| Dec 31, 2023 | -17.17% |
| Sep 30, 2023 | -14.77% |
| Jun 30, 2023 | -8.32% |
| Mar 31, 2023 | -5.13% |
| Dec 31, 2022 | 15.16% |
| Sep 30, 2022 | 22.89% |
| Jun 30, 2022 | 19.68% |
| Mar 31, 2022 | 21.85% |
| Dec 31, 2021 | 18.18% |
| Sep 30, 2021 | 25.50% |
| Jun 30, 2021 | 28.96% |